ArticleNature communications2023
In vivo bioluminescence imaging of natural bacteria within deep tissues via ATP-binding cassette sugar transporter.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06451172 (Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
Who cites it
12 citing papers in PubMed, 44 citations in OpenAlex.
- Machine-Learning Microfluidic Minute-Scale Microorganism Metrics Monitoring(M6).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.Acta pharmaceutica Sinica. B · 2026Review
- Expanded applications of bioluminescence microscopy with phasor analysis.Cell reports methods · 2026Article
- Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Magnetic poly(phages) encoded probes-based dual-mode assay for rapid determination of live Escherichia coli and Hafnia paralvei based on microfluidic chip and ATP bioluminescence meter.Mikrochimica acta · 2024Article
- Quantifying Plant Signaling Pathways by Integrating Luminescence-Based Biosensors and Mathematical Modeling.Biosensors · 2024Article
- Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Bacterial imaging in tumour diagnosis.Microbial biotechnology · 2024Review
- Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis.Journal of biomedical science · 2024Review
- Bacteria-Based Living Probes: Preparation and the Applications in Bioimaging and Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Silicon-Based Avalanche Photodiodes: Advancements and Applications in Medical Imaging.Nanomaterials (Basel, Switzerland) · 2023Review
- Advancing breast cancer diagnosis with a near-infrared fluorescence imaging smart sensor for estrogen/progesterone receptor detection.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most existing bioluminescence imaging methods can only visualize the location of engineered bacteria in vivo, generally precluding the imaging of natural bacteria. Herein, we leverage bacteria-specific ATP-binding cassette sugar transporters to internalize luciferase and luciferin by hitchhiking them on the unique carbon source of bacteria. Typically, the synthesized bioluminescent probes are made of glucose polymer (GP), luciferase, Cy5 and ICG-modified silicon nanoparticles and their substrates are made of GP and D-luciferin-modified silicon nanoparticles. Compared with bacteria with mutations in transporters, which hardly internalize the probes in vitro (i.e., ~2% of uptake rate), various bacteria could robustly engulf the probes with a high uptake rate of around 50%. Notably, the developed strategy enables ex vivo bioluminescence imaging of human vitreous containing ten species of pathogens collected from patients with bacterial endophthalmitis. By using this platform, we further differentiate bacterial and non-bacterial nephritis and colitis in mice, while their chemiluminescent counterparts are unable to distinguish them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.